Vinorelbine and cisplatin combined with endostatin as the first-line therapy for metastatic pancreatic cancer
- Author:
Dongmin CHANG
;
Can ZHOU
;
Yong ZHANG
;
Deqiang CHEN
;
Gang MA
;
Feng CAO
- Publication Type:Journal Article
- Keywords:
pancreatic cancer;
chemotherapy;
endostatin
- From:
Journal of Pharmaceutical Analysis
2010;22(1):69-封3
- CountryChina
- Language:Chinese
-
Abstract:
Objective Systemic chemotherapy for metastatic pancreatic cancer is still a difficult problem in clinical practice. The standard chemotherapy of pancreatic cancer has been gemcitabine, but the response rate is low. Therefore, it is in urgent need to explore an effective clinical therapy for this cancer. This paper, a case report, is aimed at discussing the effectiveness of vinorelbine and cisplatin combined with endostatin as the first-line therapy for metastatic pancreatic cancer. Methods A 52-year-old female patient was diagnosed with pancreas cancer with liver metastasis at the time of the first visit to our hospital. Systemic chemotherapy with vinorelbine and cisplatin combined with endostatin was conducted. Results Liver metastases almost disappeared after the first cycle of chemotherapy. The primary tumor decreased by one third in size after four cycles and disappeared after the sixth cycle according to the CT scan evaluation. Conclusion Vinorelbine and cisplatin combined with endostatin can be a promising regimen for metastatic pancreatic cancer.
